arv

In this second of 2 episodes, Shobha Swaminathan, MD, and Eric S. Daar, MD, review key data influencing their practice following the IAS 2021 Conference, including data on investigational antiretroviral agents, lenacapavir and islatravir, and alternative dosing of BPaL for MDR-TB.  

This episode includes discussion of:

• An extension of FLAIR, demonstrating virologic efficacy and safety of long-acting CAB plus RPV at Week 124
• A Week 26 safety and efficacy analysis of CAPELLA, a study of lenacapavir in heavily treatment–experienced PWH
• CALIBRATE, a study of the safety and efficacy of lenacapavir in treatment-naive PWH
• A Week 96 safety analysis of Protocol 011, evaluating islatravir plus DOR in treatment-naive patients
• A Week 24 safety and pharmacokinetic analysis of Protocol 016, evaluating oral islatravir once monthly for PrEP
• ZeNix, a phase III trial of pretomanid, bedaquiline, and linezolid (BPaL) in patients with highly resistant TB

Presenters:

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Shobha Swaminathan, MD
Associate Professor
Division of Infectious Diseases  
Department of Medicine
Rutgers New Jersey Medical School
Newark, New Jersey

Follow along with the slides at:
https://bit.ly/3hvRN5b

Content based on an online CME program supported by an educational grant from ViiV Healthcare.

In this first of 2 episodes, Shobha Swaminathan, MD, and Eric S. Daar, MD, review key data influencing their practice following the IAS 2021 Conference, including results from studies on HIV and COVID-19 outcomes; virologic and metabolic outcomes of DTG/3TC; long-acting CAB plus RPV for ART in treatment-naive PWH.  

This episode includes discussion of:

• A Global Clinical Platform that evaluated outcomes of PWH hospitalized with COVID-19
• A post hoc analysis of TANGO, evaluating the virologic and metabolic outcomes when switching to DTG/3TC vs continued 3- or 4-drug TAF-based regimens
• A Week 48 analysis of SALSA, demonstrating virologic efficacy and favorable safety profile of switching to DTG/3TC vs continuing a 3-drug ART regimen

Presenters:

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Shobha Swaminathan, MD
Associate Professor
Division of Infectious Diseases  
Department of Medicine
Rutgers New Jersey Medical School
Newark, New Jersey

Follow along with the slides at:
https://bit.ly/3hvRN5b

Content based on an online CME program supported by an educational grant from ViiV Healthcare.

Live Real Estate Training with Chad Corbett, Episode #22:  How to Calculate Maximum  Allowable Offer; Nurturing B2B Referral Relationships; and Navigating Property Clean Outs

Full Show Notes and links to MAO spreadsheet and other resources mentioned: https://probatemastery.com/how-to-calculate-maximum-allowable-offer-mao-for-wholesale-and-investment-on-the-back-of-a-napkin 

Watch with video on YouTube:  https://youtu.be/TG6On9MCnQk

MUST JOIN! The Estate Professionals Mastermind Group has productivity challenges, high-energy community support, and bite-sized content, and is FREE to join. Join Now



Time Stamps (YouTube links):
0:00 Introductions
0:49 How to Calculate Your Max Allowable Offer: ARV, Repair Costs, and Your Target Profit
4:25 The 70% Rule in 60 Seconds: The Back Of The Napkin Method
9:06 How to Estimate Repair Value and Learn Your Cosmetic vs. Mechanical Repairs per Square Foot
15:06 What is an Application to Relieve the Estate From Administration?
15:36 How to Offer Free Services Without Expending Your Own Capital
17:12 Costs of Probate Services: How to Turn Vendor Partners into Your Bank
19:12 How to Target the Right Attorneys for Referral Relationships
27:24 Nurturing Vendor Relationships and Generating Real Estate Referrals
35:18 Transaction Engineering: Three Ways to Handle Personal Property Cleanouts

More Resources For You:
Facebook Community
Probate Mastery Certification Course
Chad's New YouTube Channel

Socials:
Chad's Instagram
Chad's LinkedIn
Katt's Instagram
Katt's LinkedIn


More Recent Content:

• Guide: 7 Tips for Consistent Lead Generation when Working Solo / as a Small Team
   
• Action Plan: 18 Prompts for YouTube Videos that will Jumpstart your Probate Real Estate Marketing
   
• Group Coaching: How To Access Equity in Mom’s House | Handling Objections from Multiple Heirs 

Learn more at www.probatemastery.com

In this series of 3 episodes, Geeta Gupta, MD, discusses strategies for optimizing ART in heavily treatment–experienced patients with HIV, including management of virologic failure and switching ART in virologically suppressed patients with underlying resistance. The 3 episodes will include analyses from:

• BENCHMRK, which demonstrated that the number of active drugs predicts outcomes in treatment-experienced patients
• TMB-301, a study that added the monoclonal antibody ibalizumab in pretreated patients with multidrug-resistant HIV and demonstrated significant decreases in HIV-1 RNA
• BRIGHTE, which showed that the addition of fostemsavir in heavily treatment–experienced patients with HIV led to a significant decrease in HIV-1 RNA
• VIKING-3, a study that demonstrated the addition of DTG dosed BID in INI-resistant patients was effective in decreasing HIV-1 RNA
• SWITCHMRK, a study that showed underlying resistance matters when deciding to switch regimens in a treatment-experienced, virologically suppressed patient, especially when switching to a regimen with a low barrier to resistance
• DAWNING, a study that demonstrated that DTG, when added to 2 NRTIs, was superior to RTV-boosted LPV in patients with virologic failure on an NNRTI plus 2 NRTIs
• BRAAVE, which evaluated safety and efficacy of switching to BIC/FTC/TAF in Black patients virologically suppressed on 2 NRTIs plus a third agent

In addition, Dr. Gupta reviews current DHHS ART guideline recommendations related to managing virologic failure, including drug resistance testing and drug selection, as well as switching recommendations in patients with viral suppression and underlying drug resistance.

Presenter:

Geeta Gupta, MD
Professor
Director, AIDS Education and Training Center
University of California, Irvine
Orange, California

Follow along with the slides at:
https://bit.ly/3zxKBfL

Content based on an online CME program supported by an educational grant from ViiV Healthcare.

Link to full program:
https://bit.ly/3ux6FF8

In this series of 3 episodes, Geeta Gupta, MD, discusses strategies for optimizing ART in heavily treatment–experienced patients with HIV, including management of virologic failure and switching ART in virologically suppressed patients with underlying resistance. The 3 episodes will include analyses from:

• BENCHMRK, which demonstrated that the number of active drugs predicts outcomes in treatment-experienced patients
• TMB-301, a study that added the monoclonal antibody ibalizumab in pretreated patients with multidrug-resistant HIV and demonstrated significant decreases in HIV-1 RNA  
• BRIGHTE, which showed that the addition of fostemsavir in heavily treatment–experienced patients with HIV led to a significant decrease in HIV-1 RNA  
• VIKING-3, a study that demonstrated the addition of DTG dosed BID in INI-resistant patients was effective in decreasing HIV-1 RNA
• SWITCHMRK, a study that showed underlying resistance matters when deciding to switch regimens in a treatment-experienced, virologically suppressed patient, especially when switching to a regimen with a low barrier to resistance
• DAWNING, a study that demonstrated that DTG, when added to 2 NRTIs, was superior to RTV-boosted LPV in patients with virologic failure on an NNRTI plus 2 NRTIs
• BRAAVE, which evaluated safety and efficacy of switching to BIC/FTC/TAF in Black patients virologically suppressed on 2 NRTIs plus a third agent

In addition, Dr. Gupta reviews current DHHS ART guideline recommendations related to managing virologic failure, including drug resistance testing and drug selection, as well as switching recommendations in patients with viral suppression and underlying drug resistance.

Presenter:

Geeta Gupta, MD
Professor
Director, AIDS Education and Training Center
University of California, Irvine
Orange, California

Follow along with the slides at:
https://bit.ly/3zxKBfL

Content based on an online CME program supported by an educational grant from ViiV Healthcare.

Link to full program:
https://bit.ly/3ux6FF8

In this series of 3 episodes, Geeta Gupta, MD, discusses strategies for optimizing ART in heavily treatment–experienced patients with HIV, including management of virologic failure and switching ART in virologically suppressed patients with underlying resistance. The 3 episodes will include analyses from:

• BENCHMRK, which demonstrated that the number of active drugs predicts outcomes in treatment-experienced patients
• TMB-301, a study that added the monoclonal antibody ibalizumab in pretreated patients with multidrug-resistant HIV and demonstrated significant decreases in HIV-1 RNA
• BRIGHTE, which showed that the addition of fostemsavir in heavily treatment–experienced patients with HIV led to a significant decrease in HIV-1 RNA  
• VIKING-3, a study that demonstrated the addition of DTG dosed BID in INI-resistant patients was effective in decreasing HIV-1 RNA
• SWITCHMRK, a study that showed underlying resistance matters when deciding to switch regimens in a treatment-experienced, virologically suppressed patient, especially when switching to a regimen with a low barrier to resistance
• DAWNING, a study that demonstrated that DTG, when added to 2 NRTIs, was superior to RTV-boosted LPV in patients with virologic failure on an NNRTI plus 2 NRTIs
• BRAAVE, which evaluated safety and efficacy of switching to BIC/FTC/TAF in Black patients virologically suppressed on 2 NRTIs plus a third agent

In addition, Dr. Gupta reviews current DHHS ART guideline recommendations related to managing virologic failure, including drug resistance testing and drug selection, as well as switching recommendations in patients with viral suppression and underlying drug resistance.

Presenter:

Geeta Gupta, MD
Professor
Director, AIDS Education and Training Center
University of California, Irvine
Orange, California

Follow along with the slides at:
https://bit.ly/3zxKBfL

Content based on an online CME program supported by an educational grant from ViiV Healthcare.

Link to full program:
https://bit.ly/3ux6FF8

In this episode, Chloe Orkin, MBChB, FRCP, MD, discusses exciting new HIV data reported at the virtual CROI 2021, including new findings on HIV PrEP, HIV and COVID-19, ART in pregnancy and the postpartum period, as well as on the comparative efficacy of various ARV regimens.

Presenter:

Chloe Orkin, MBChB, FRCP, MD
Professor of HIV  
Queen Mary University of London
Consultant Physician  
Lead for HIV Research  
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom

Content based on a CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.

Link to full program:
http://bit.ly/3eUPAj9

In this episode, Brian Wood, MD, discusses HIV treatment safety and tolerability data from 2020 conferences and addresses how he manages ARV-associated weight gain his patients and how the latest data on ART safety during conception and pregnancy impact his treatment recommendations.

Presenters:

Brian Wood, MD
Associate Professor of Medicine
Division of Allergy and Infectious Diseases
University of Washington
Seattle, Washington

Content based on an online CME/CE/CPE-certified program supported by educational grants from Janssen Therapeutics, Division of Janssen Products, LP.

Link to full program:
https://bit.ly/38YZVrz

Föreläsningen organiserades i samarbete med Alhambra studentförening och Gröna Rummet Lund för muslimska studenter.

Besök gärna vår hemsida: www.koranpodden.se.

Följ vårt arbete

facebook.com/koranpodden

instagram.com/koranpodden/

Stöd Koranpodden

Om du finner någon glädje eller värde i vad jag gör, snälla överväg att donera ett valfritt belopp. Alla donationer går till att utveckla och marknadsföra Koranpodden. Swisha ett frivilligt belopp till swish 123 669 10 18 (Support Koranpodden) eller via bankgiro 5271-8053.

Bli månadsgivare! Klicka här.

JOIN NOW: Probate Mastermind And Networking Community: https://www.facebook.com/groups/alltheleadsmastermind

PROBATE LEADS: https://alltheleads.com/probate-leads

PROBATE MASTERY COURSE: www.ProbateMastery.com


FULL EPISODE SUMMARY AND RESOURCE LIST ON ALLTHELEADS.COM


Learn how to find fix and flips that meet the 70% rule for real estate investing. Chad shares his strategy for winning face-to-face appointments and preventing squatters at the same time.  Chad, Bruce, and Patti discuss three ways to monetize leads that are keeping or have already sold the property.  Probate Real Estate Expert Rodger Lecy gives advice for agents and investors in small markets - You can really make BIG MONEY.



Call Re-Cap (Time Stamps link to YouTube)

• Preventing Squatters: Win Appointments With THIS Strategy (1:34)
• INVESTOR BEST PRACTICES: Winning Multiple Offer Situations WITHOUT Raising Your Offer (4:30)
• Take This Probate Course As Many Times As You’d Like: Probate Mastery (9:07)
• Squatters and Vacant Insurance Policy: Two Ways To Win Appointments With Sellers While Cold Calling (9:45)
• Finding Real Estate In Trusts/Entities Outside of Probate (11:59)
• Overcoming Objections: “How Much Does This Cost?” Objection [Role Play] (16:34)
• Deal Structuring: Medicaid Liens, Special vs. General Warranty Deeds, and Mitigating Risk (23:03)
• The 70% Rule in House Flipping: How To Find The Deals Cash Buyers Are Looking For (34:15)
• The BEST Referrals: Out-of-State Personal Representatives (35:49)
• Small Market or Big Market: How To Succeed With Probate Real Estate (43:40)
• Nurturing Probate Leads Before Letters of Testamentary are Issued (49:04)
• How To Find and Fund Fix and Flip Properties: Probate Wholesaling and Investing (52:14)
• Probate Expert Rodger Lecy Shares Advice For Making BIG MONEY in SMALL MARKETS with Probate Real Estate (59:05)

Full Mastermind Playlist on YouTube

Join the Probate Mastermind Group on Facebook

CHAD CORBETT'S PROBATE REAL ESTATE CERTIFICATION COURSE: www.ProbateMastery.com

Dutch Jackson sits down on The Titanium Vault podcast to share how his real estate hip hop album, D4D, has opened up relationships and opportunities for him within the real estate investing industry. He also shares how he is now a part of the Titanium family doing acquisitions and dispositions for Titanium Investments, a partner in Titanium Vision and going to be hosting the new raw real estate investing podcast, Titanium Underground.

Get the D4D album by Dutch Jackson today!!

D4D Spotify
https://open.spotify.com/album/2HKWWf...


D4D ITUNES -
http://itunes.apple.com/album/id14816...

D4D APPLE MUSIC -
http://itunes.apple.com/album/id/1481...

D4D Amazon Music - https://music.amazon.com/albums/B07YG...

The premier episode tells the stories of long-term survivors, people who have been living with HIV for over 25 years. Guests Allan, John, Rod, Murray and Muluba tell us about the early days of the epidemic, early and current medications, loss and hopes for the future.

Positively Speaking is a project by Casey House hospital, visit our website to learn more.